Proactive Investors - Run By Investors For Investors
52-week High/Low: $33.81 / $10.85
Sector: Pharmaceuticals
Market Cap: $24,199.10M
Teva Pharmaceutical Industries (:TEVA)

Teva Pharmaceutical Industries

Teva Pharmaceutical Industries develops, produces and markets generic drugs covering a wide range treatment categories.

Teva Pharmaceutical Industries

Interactive graph

col 3
col 4
col 5
col 6

Teva Pharmaceutical Industries Timeline

Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. are teaming up to develop and commercialise globally commercialize fasinumab, Regeneron’s investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain
Teva Pharmaceutical Industries (NYSE:TEVA), an Israeli drugmaker, agreed to buy Dublin-based Allergan PLC's (NYSE:AGN) generic pharmaceuticals business for $40.5 billion in cash and stock, and dropped its hostile offer for Mylan (NASDAQ:MYL). Teva will pay $33.75 billion in cash and $6.75 billion worth of shares at...
Teva’s Board unanimously approved the transaction, which could be finalized by the end of the year. However, Teva will face some obstacles as not have a smooth path as Mylan’s unsolicited US28.9 billion bid for Perrigo Co. (NYSE:PRGO) on April 17 was meant to act as a buttress, making the Canonsburg (PA) run...

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use